Table 2.
Demographics and Baseline Characteristics by Edoxaban Dose
| Patients with no dose-reduction criteria met |
Patients who met ≥1 dose-reduction criterion |
|||
|---|---|---|---|---|
| Recommended 60 mg (n=1,293) |
Nonrecommended 30 mg (n=601) |
Recommended 30 mg (n=1,088) |
Nonrecommended 60 mg (n=377) |
|
| Sex, male, n (%) | 1,000 (77.3) | 388 (64.6) | 437 (40.2) | 171 (45.4) |
| Age, years, mean±SD | 67.0±8.9 | 71.4±8.9 | 77.3±8.0 | 71.8±8.9 |
| Weight, kg, mean±SD | 73.9±9.8 | 72.4±9.1 | 57.1±9.8 | 58.3±7.8 |
| Body mass index, kg/m2, mean±SD | 26.6±3.4 | 26.8±3.4 | 23.1±3.5 | 23.1±2.9 |
| eGFR, mL/min/1.73 m2, mean±SD | 78.1±19.9 | 72.9±20.6 | 44.4±16.0 | 54.5±16.9 |
| CHA2DS2-VASc, mean±SD | 2.6±1.4 | 3.0±1.4 | 3.8±1.4 | 3.3±1.4 |
| HAS-BLED, mean±SD | 2.1±1.0 | 2.3±1.0 | 2.5±1.1 | 2.2±1.1 |
| Type of AF, n (%) | ||||
| Paroxysmal | 559 (43.3) | 272 (45.3) | 505 (46.5) | 173 (46.0) |
| Persistent | 337 (26.1) | 143 (23.8) | 235 (21.6) | 77 (20.5) |
| Long-standing persistent | 150 (11.6) | 109 (18.2) | 120 (11.0) | 44 (11.7) |
| Permanent | 246 (19.0) | 76 (12.7) | 227 (20.9) | 82 (21.8) |
| Diabetes mellitus, n (%) | 399 (30.9) | 182 (30.3) | 319 (29.3) | 99 (26.3) |
| Hypertension, n (%) | 916 (70.8) | 435 (72.4) | 821 (75.5) | 255 (67.6) |
| Heart failure, n (%)* | 111 (8.6) | 70 (11.6) | 195 (17.9) | 42 (11.1) |
| COPD, n (%) | 52 (4.0) | 23 (3.8) | 64 (5.9) | 22 (5.8) |
| Peripheral artery disease, n (%) | 8 (0.6) | 3 (0.5) | 14 (1.3) | 0 |
| History of ischemic stroke, n (%) | 198 (15.3) | 76 (12.6) | 151 (13.9) | 82 (21.8) |
| History of major or CRNM bleeding, n (%) | 26 (2.0) | 18 (3.0) | 51 (4.7) | 11 (2.9) |
| History of major bleeding, n (%) | 18 (1.4) | 15 (2.5) | 34 (3.1) | 9 (2.4) |
*A medical history of heart failure was determined if the patient met one of the following criteria: documented CHF or, if CHF was not reported, documentation of ischemic cardiomyopathy; ejection fraction <40%; frequent dyspnea (≥1/day) without chronic obstructive pulmonary disease and with documented severe valvular heart disease, coronary artery disease post-myocardial infarction, valve replacement, or hypertension treated with ≥3 antihypertensive drugs. Abbreviations as in Table 1.